Dr. Dina Khalaf explains the ASCERTAIN-V, MyeloMATCH MM1MDS-A01 and HOVON 181 trials and what patients with AML or MDS should ask before enrolling.
News|Articles|September 18, 2026
Blood Cancer Treatments in the FDA Pipeline: What Could Come Next
Author(s)Spencer Feldman
Fact checked by: CURE staff
September is Blood Cancer Awareness Month, and the pipeline for leukemia, lymphoma and myeloma is as active as it has been in years.
Advertisement
Advertisement
One CAR T-cell therapy for multiple myeloma is awaiting an FDA decision this year, and late-stage trials across myeloma, lymphoma and leukemia could produce the next filings. Here's what to watch.
Related to this article
Dr. Dina Khalaf breaks down three clinical trials testing oral and targeted regimens for acute myeloid leukemia and myelodysplastic syndrome.
After cancer, taking time to rest and travel can create space to heal, reconnect and remember that life is about more than simply surviving.
Children with diffuse midline glioma who took Keppra lived a median of 20.96 months, compared with 9.92 months for those who did not, a new study found.
A phase 1 trial treated 15 patients with breast cancer that spread to the spinal fluid using a vaccine made from their own immune cells. One patient is now more than three years from diagnosis.
Deborah A. McDowell of OAW explains how patients can prepare for hair loss before chemotherapy starts.
FDA approves an updated Ibtrozi label for locally advanced or metastatic ROS1-positive NSCLC, reflecting nearly four years of response data.
Gentle movement during cancer treatment can help maintain strength, mobility and balance. Follow Jennifer Tipton’s simple exercises to keep your body moving.
Advertisement
Advertisement